The impact of the M184V substitution on drug resistance and viral fitness.
about
General Catalytic Deficiency of Hepatitis C Virus RNA Polymerase with an S282T Mutation and Mutually Exclusive Resistance towards 2'-Modified Nucleotide AnaloguesReappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infectionA polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activityModerate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National SurveyEtravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infectionPrevalence of primary resistance at baseline in acutely and recently infected subjects enrolled in AIDS clinical trials group protocol 371.Fitness impaired drug resistant HIV-1 is not compromised in cell-to-cell transmission or establishment of and reactivation from latencyHIV-1 diversity after a class switch failure.Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations.Human leukocyte antigen B27 selects for rare escape mutations that significantly impair hepatitis C virus replication and require compensatory mutations.Targeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1.Immune-mediated attenuation of HIV-1Deep sequencing reveals minor protease resistance mutations in patients failing a protease inhibitor regimen.Uncommon pathways of immune escape attenuate HIV-1 integrase replication capacity.Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.Subunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase.Retrovirus reverse transcriptases containing a modified YXDD motif.Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.Biochemical mechanism of HIV-1 resistance to rilpivirine.Nucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2.In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine.Comparative efficacy of Lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trialsHuman Immunodeficiency Virus-1 Sequence Changes and Drug Resistance Mutation Among Virologic Failures of Lopinavir/Ritonavir Monotherapy: AIDS Clinical Trials Group Protocol A5230.Comparative analysis of in vitro processivity of HIV-1 reverse transcriptases containing mutations 65R, 74V, 184V and 65R+74V.The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) studyHIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa.Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1.The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.Human immunodeficiency virus type 1: resistance to nucleoside analogues and replicative capacity in primary human macrophages.Reduced replication capacity of NL4-3 recombinant viruses encoding reverse transcriptase-integrase sequences from HIV-1 elite controllers.Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy.High Levels of Dual-Class Drug Resistance in HIV-Infected Children Failing First-Line Antiretroviral Therapy in Southern Ethiopia.Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection.Monitoring HIV drug resistance in treatment-naive individuals: molecular indicators, epidemiology and clinical implications
P2860
Q27477760-68082266-6338-4ACE-A665-A281806FBDE0Q28478934-D19E4CF5-653B-46A0-8320-98A18016DA2FQ28533996-3F2D9CCD-139A-43C5-8DBB-9035345A5ED5Q28554729-23DF88D8-45D1-4166-80CC-CE03B0980690Q33973857-2C0D9469-9DB4-4EF4-BF60-985222219370Q34085443-60F311F6-6424-4AF8-AC44-8EB0BCA7E503Q34303589-B0253F39-4E5D-4723-BCDC-F8EAB51D8CE7Q34399268-808B8312-7E5A-46BF-A16F-85BAD67F080DQ35363054-7B42EE10-AFFA-4B51-B658-A78B87A90694Q35446259-A9369E75-7C92-4972-9052-4A14102AE7A6Q35747309-ACB2CA27-040B-404A-A0A5-EC54FE1048C5Q35798108-A40804D8-4A33-4E87-AEE4-2142C1E6B068Q36023047-65CA5C3C-6D29-48F0-8504-82A8DAF4C17AQ36086711-F1B0B462-4D63-4585-A911-6F8C7E137E02Q36099119-68625918-5836-40D4-B65C-45C77350AE29Q36172087-31E13E65-5E52-426E-8797-8451F0A5E8C1Q36186797-828CD86B-9195-4C4C-91B4-37281DD20182Q36246775-D43B5F36-22AF-4074-82BA-CDCBB2B08391Q36368294-DEFA860D-2E0B-4240-BDD2-05C7647B6673Q37072022-F01625F6-228E-4900-AB2D-4DC153C8AACEQ37099813-BF6C0BBC-FF4F-45DD-8620-481DDE5761F4Q37296706-76B20E05-8CB3-4043-8C82-9EC950627F15Q37305622-FDA603C6-410E-48F7-BDC0-745E6D8F64ABQ37404676-8C65D8A2-0AB9-49F2-8772-DC5D981D23F8Q37547275-5E919783-E78C-4543-B862-ECC3F3CFCC0AQ38376451-C1422C54-0745-41AF-8F0A-BA542B3DA0C6Q39360243-E7BDDEDF-B350-4D72-BAD1-DC11AA840364Q39599947-443BE479-8B6D-4034-AB41-267B0A301278Q39724626-425EF5F0-4191-4749-ACD0-37052ECE7F6FQ40173457-65E5FD25-A194-4F21-A9C6-CC8CEE1636C1Q42718488-9AC978C8-BDD8-4BA9-AF4C-57AE17BFA63BQ43077557-CAF51F82-52A0-49DB-8308-B0CF291D4457Q45471093-3B7F4B9D-BCAE-465F-A16A-4E75DDC34554Q47547186-E7FB6A24-DE4D-4771-B046-F0CFAF737373Q52374199-08E5B1AC-60D4-4967-8923-66B7D6491693Q57708766-9AEA2E5F-38EB-47B1-AD63-6F0AA5CE3FDB
P2860
The impact of the M184V substitution on drug resistance and viral fitness.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The impact of the M184V substitution on drug resistance and viral fitness.
@ast
The impact of the M184V substitution on drug resistance and viral fitness.
@en
type
label
The impact of the M184V substitution on drug resistance and viral fitness.
@ast
The impact of the M184V substitution on drug resistance and viral fitness.
@en
prefLabel
The impact of the M184V substitution on drug resistance and viral fitness.
@ast
The impact of the M184V substitution on drug resistance and viral fitness.
@en
P2860
P356
P1476
The impact of the M184V substitution on drug resistance and viral fitness.
@en
P2093
Mark A Wainberg
P2860
P304
P356
10.1586/14787210.2.1.147
P577
2004-02-01T00:00:00Z